Endocrine Abstracts

IntroductionAdrenocortical Carcinoma (ACC) is a rare aggressive cancer which carries a poor prognosis. Adjuvant mitotane improves survival but is limited by poor response rates and resistance following tumour recurrence. Mitotane’s efficacy has been attributed to intracellular accumulation of toxic free cholesterol (FC) predominantly through inhibition of cholesterol storage through SOAT1. Yet SOAT1 specific inhibitors demonstrate inferior efficacy ...

Management of ACC is difficult. Diagnosis usually occurs at an advanced disease stage. Resection of localised disease offers a potential cure, but recurrence is common (75-85% of cases). For the treatment of unresectable/metastatic disease, mitotane is the only approved drug, alongside M-EDP chemotherapy. Mitotane has a narrow therapeutic window and is poorly tolerated. Additionally, ACC is a heterogenous disease regarding phenotype, genotype, disease progression and resistanc...

Introduction: Primary Aldosteronism is the most common cause of secondary hypertension. First-line treatment; adrenalectomy resects adrenal nodules and adjacent normal tissue, limiting suitability to those who present with unilateral disease. Use of thermal ablation represents an emerging approach as a possible minimally invasive therapy for unilateral and bilateral disease, to target and disrupt hypersecreting aldosterone producing adenomas, while preserving adjacent normal a...

IntroductionPrimary Aldosteronism (PA) is the commonest secondary cause of hypertension. Mainstay therapy, adrenalectomy resects both hypersecreting and adjacent normal tissue. It is therefore only suitable for patients with unilateral disease (40% cases), whom are surgical candidates. Thermal therapy presents a plausible minimally invasive therapy, to target and disrupt hypersecreting aldosterone producing adenomas (APA), while also preserving adjacent ...